Oncogenic BRAF Induces Senescence and Apoptosis through Pathways Mediated by the Secreted Protein IGFBP7

Cell

Volumn 132, Issue 3, 2008, Pages 363-374

  Wajapeyee, Narendra ^a   Serra, Ryan W ^a   Zhu, Xiaochun ^a   Mahalingam, Meera ^b   Green, Michael R ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

HUMDISEASE; SIGNALING

Indexed keywords

B RAF KINASE; BINDING PROTEIN; PROTEIN IGFBP7; SOMATOMEDIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MELANOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA INTERFERENCE; SENESCENCE; SENSITIVITY ANALYSIS; UPREGULATION;

MUS;

EID: 38849168162     PISSN: 00928674     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cell.2007.12.032     Document Type: Article

References (39)

1. Beausejour C.M., Krtolica A., Galimi F., Narita M., Lowe S.W., Yaswen P., and Campisi J. Reversal of human cellular senescence: roles of the p53 and p16 pathways. EMBO J. 22 (2003) 4212-4222
2. Ben-Porath I., and Weinberg R.A. The signals and pathways activating cellular senescence. Int. J. Biochem. Cell Biol. 37 (2005) 961-976
3. Bennett D.C. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22 (2003) 3063-3069
4. Bultman S., Gebuhr T., Yee D., La Mantia C., Nicholson J., Gilliam A., Randazzo F., Metzger D., Chambon P., Crabtree G., and Magnuson T. A Brg1 null mutation in the mouse reveals functional differences among mammalian SWI/SNF complexes. Mol. Cell 6 (2000) 1287-1295
5. Campisi J. Suppressing cancer: the importance of being senescent. Science 309 (2005) 886-887
6. Chin L., Merlino G., and DePinho R.A. Malignant melanoma: modern black plague and genetic black box. Genes Dev. 12 (1998) 3467-3481
7. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
8. Dhomen N., and Marais R. New insight into BRAF mutations in cancer. Curr. Opin. Genet. Dev. 17 (2007) 31-39
9. Dimri G.P., Lee X., Basile G., Acosta M., Scott G., Roskelley C., Medrano E.E., Linskens M., Rubelj I., Pereira-Smith O., et al. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA 92 (1995) 9363-9367
10. Emrick M.A., Lee T., Starkey P.J., Mumby M.C., Resing K.A., and Ahn N.G. The gatekeeper residue controls autoactivation of ERK2 via a pathway of intramolecular connectivity. Proc. Natl. Acad. Sci. USA 103 (2006) 18101-18106
11. Formstecher E., Ramos J.W., Fauquet M., Calderwood D.A., Hsieh J.C., Canton B., Nguyen X.T., Barnier J.V., Camonis J., Ginsberg M.H., and Chneiweiss H. PEA-15 mediates cytoplasmic sequestration of ERK MAP kinase. Dev. Cell 1 (2001) 239-250
12. Frommer M., McDonald L.E., Millar D.S., Collis C.M., Watt F., Grigg G.W., Molloy P.L., and Paul C.L. A genomic sequencing protocol that yields a positive display of 5-methylcytosine residues in individual DNA strands. Proc. Natl. Acad. Sci. USA 89 (1992) 1827-1831
13. Gazin C., Wajapeyee N., Gobeil S., Virabasius C.M., and Green M.R. An elaborate pathway required for Ras-mediated epigenetic silencing. Nature 449 (2007) 1073-1077
14. Gray-Schopfer V., Wellbrock C., and Marais R. Melanoma biology and new targeted therapy. Nature 445 (2007) 851-857
15. Hartman S.E., Bertone P., Nath A.K., Royce T.E., Gerstein M., Weissman S., and Snyder M. Global changes in STAT target selection and transcription regulation upon interferon treatments. Genes Dev. 19 (2005) 2953-2968
16. Hingorani S.R., Jacobetz M.A., Robertson G.P., Herlyn M., and Tuveson D.A. Suppression of BRAF(V599E) in human melanoma abrogates transformation. Cancer Res. 63 (2003) 5198-5202
17. Hoeflich K.P., Gray D.C., Eby M.T., Tien J.Y., Wong L., Bower J., Gogineni A., Zha J., Cole M.J., Stern H.M., et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res. 66 (2006) 999-1006
18. Leppa S., Saffrich R., Ansorge W., and Bohmann D. Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation. EMBO J. 17 (1998) 4404-4413
19. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., and Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436 (2005) 720-724
20. Mooi W.J., and Peeper D.S. Oncogene-induced cell senescence-halting on the road to cancer. N. Engl. J. Med. 355 (2006) 1037-1046
21. Mutaguchi K., Yasumoto H., Mita K., Matsubara A., Shiina H., Igawa M., Dahiya R., and Usui T. Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res. 63 (2003) 7717-7723
22. Narita M., Krizhanovsky V., Nunez S., Chicas A., Hearn S.A., Myers M.P., and Lowe S.W. A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126 (2006) 503-514
23. Oh Y., Nagalla S.R., Yamanaka Y., Kim H.S., Wilson E., and Rosenfeld R.G. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J. Biol. Chem. 271 (1996) 30322-30325
24. Park S., Yeung M.L., Beach S., Shields J.M., and Yeung K.C. RKIP downregulates B-Raf kinase activity in melanoma cancer cells. Oncogene 24 (2005) 3535-3540
25. Peeper D.S., and Mooi W.J. Pathogenesis of melanocytic naevi: growth arrest linked with cellular senescence?. Histopathology 41 (2002) S139-S143
26. Pfaffl M.W. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 29 (2001) e45
27. Pollock P.M., Harper U.L., Hansen K.S., Yudt L.M., Stark M., Robbins C.M., Moses T.Y., Hostetter G., Wagner U., Kakareka J., et al. High frequency of BRAF mutations in nevi. Nat. Genet. 33 (2003) 19-20
28. Ruan W.J., Lin J., Xu E.P., Xu F.Y., Ma Y., Deng H., Huang Q., Lv B.J., Hu H., Cui J., et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J. Zhejiang Univ. Sci. B 7 (2006) 929-932
29. Satyamoorthy K., Li G., Gerrero M.R., Brose M.S., Volpe P., Weber B.L., Van Belle P., Elder D.E., and Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63 (2003) 756-759
30. Sharma A., Trivedi N.R., Zimmerman M.A., Tuveson D.A., Smith C.D., and Robertson G.P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65 (2005) 2412-2421
31. Solit D.B., Garraway L.A., Pratilas C.A., Sawai A., Getz G., Basso A., Ye Q., Lobo J.M., She Y., Osman I., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439 (2006) 358-362
32. Sparrow L.E., Eldon M.J., English D.R., and Heenan P.J. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Am. J. Dermatopathol. 20 (1998) 255-261
33. Swisshelm K., Ryan K., Tsuchiya K., and Sager R. Enhanced expression of an insulin growth factor-like binding protein (mac25) in senescent human mammary epithelial cells and induced expression with retinoic acid. Proc. Natl. Acad. Sci. USA 92 (1995) 4472-4476
34. Tournier C., Whitmarsh A.J., Cavanagh J., Barrett T., and Davis R.J. The MKK7 gene encodes a group of c-Jun NH2-terminal kinase kinases. Mol. Cell. Biol. 19 (1999) 1569-1581
35. Wajapeyee N., and Somasundaram K. Cell cycle arrest and apoptosis induction by activator protein 2alpha (AP-2alpha) and the role of p53 and p21WAF1/CIP1 in AP-2alpha-mediated growth inhibition. J. Biol. Chem. 278 (2003) 52093-52101
36. Wang Y.L., Uhara H., Yamazaki Y., Nikaido T., and Saida T. Immunohistochemical detection of CDK4 and p16INK4 proteins in cutaneous malignant melanoma. Br. J. Dermatol. 134 (1996) 269-275
37. Wilson E.M., Oh Y., and Rosenfeld R.G. Generation and characterization of an IGFBP-7 antibody: identification of 31kD IGFBP-7 in human biological fluids and Hs578T human breast cancer conditioned media. J. Clin. Endocrinol. Metab. 82 (1997) 1301-1303
38. Wilson H.M., Birnbaum R.S., Poot M., Quinn L.S., and Swisshelm K. Insulin-like growth factor binding protein-related protein 1 inhibits proliferation of MCF-7 breast cancer cells via a senescence-like mechanism. Cell Growth Differ. 13 (2002) 205-213
39. Zhu J., Woods D., McMahon M., and Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes Dev. 12 (1998) 2997-3007